The Rescheduling Trade Nobody’s Pricing Correctly
There’s a peculiar mispricing happening in cannabis markets right now, and it has nothing to do with THC potency, hostile takeovers, or hemp beverage carve-outs. It has to do with time. Specifically, the difference between the time it takes to reschedule a drug and the time it takes to actually build the infrastructure that makes rescheduling matter.
Wall Street, to the extent it pays attention to this sector at all, tends to treat federal cannabis rescheduling as a binary catalyst. Schedule I to Schedule III, 280E goes away, multiples re-rate, done. That’s the trade thesis in its simplest form, and it’s not wrong, exactly. Attorney General Todd Blanche’s April order moving state-licensed medical cannabis to Schedule III already delivered a real tax benefit to operators holding that status, and the DEA’s own final brief in the broader administrative proceeding argues plainly that marijuana no longer meets the statutory criteria for Schedule I. The Administrative Law Judge overseeing that process has the full record in hand. A recommendation could land at any point, and once DEA Administrator Terrence Cole acts on it, the tax and banking mechanics of running a U.S. cannabis company change overnight.
But there’s a second-order question analysts covering this space have mostly ignored: once the legal switch flips, who actually has anything built to plug into it?
This is where the U.S.-centric framing of the rescheduling trade starts to look incomplete. American cannabis companies have spent the better part of a decade operating under Schedule I, which meant no meaningful pharmaceutical-grade R&D, no standardized clinical data infrastructure, no integration with insurers or physicians in any format resembling how actual medicine gets delivered and reimbursed. The industry built retail. It built brands. It built cultivation and extraction at scale. What it didn’t build, because federal law made it functionally impossible, is the connective tissue between cannabis and the healthcare system itself: treatment protocols, drug-interaction screening, physician education pipelines, insurance reimbursement rails.
Canada solved a version of this problem eight years ago, and the company that has spent the longest time working the seams of that legal window is Avicanna Inc. (TSX: AVCN).
Avicanna isn’t a large-cap name, and it shouldn’t be mistaken for one. But its relevance to the U.S. rescheduling thesis isn’t about market cap, it’s about what a company can accomplish when it’s allowed to actually finish the experiment. Since Canada’s 2018 legalization, Avicanna has run without the guardrails American operators have lived under: full federal legality, an open runway for clinical collaboration, and the ability to build medical infrastructure without having to route around a controlled-substance classification. The company’s RHO Phyto line now spans more than 50 commercialized SKUs of non-inhaled, dose-controlled cannabinoid formulations, transdermal gels, sublingual sprays, rapid-onset capsules and gummies, a portfolio built specifically to give physicians something that looks and behaves like conventional medicine rather than smokable flower. Layered on top of that is MyMedi.ca, a national, pharmacist-supported platform handling patient intake, treatment planning, drug-interaction screening and insurance reimbursement, with roughly 80% of its revenue currently covered by insurance. That’s not a dispensary model. That’s closer to a specialty pharmacy model, which happens to be exactly the kind of infrastructure U.S. rescheduling doesn’t create on its own.
CEO Aras Azadian has been fairly direct about how he frames this distinction. “I don’t view medical cannabis as a product, I view it as a service,” he said in a recent conversation, and it’s a framing that matters more than it sounds. A product can be duplicated by anyone with a cultivation license and a filling machine. A service, patient support, physician integration, treatment protocols built around specific clinical indications, takes years to construct and even longer to validate with real-world data. That’s the piece rescheduling doesn’t hand American operators for free.
None of this means the transition is simple, or that Avicanna’s playbook drops into the U.S. market intact. Federal rescheduling and state-level regulatory fragmentation are two different problems, and a platform built for Canada’s single-payer-adjacent healthcare system will need real adaptation before it means anything to a U.S. insurer or a state medical board. Azadian himself has acknowledged the bottleneck isn’t enthusiasm, it’s timing. “They think rescheduling is going to happen, but once it actually is announced, then you’re going to start seeing a lot of things start to move,” he said, describing conversations already underway with U.S. partners who are waiting on the final domino before committing capital.
That waiting posture is, in a sense, the entire trade. Capital allocators watching this sector are pricing in the legal event and largely ignoring the execution gap that follows it. The operators, pharmacy chains, or health systems that move fastest post-rescheduling won’t be the ones simply relieved of a 280E tax burden, they’ll be the ones with something to license, integrate, or acquire on day one. Right now, there are vanishingly few assets in North America that fit that description, and fewer still with a decade of clinical data behind them.
Whether Avicanna specifically ends up being the vehicle U.S. partners license, acquire, or simply study is a separate question from whether the underlying thesis holds. The thesis does hold. American cannabis rescheduling removes a legal barrier. It does not, by itself, manufacture the clinical infrastructure, physician relationships, or reimbursement pathways that determine whether medical cannabis actually functions as medicine rather than as a retail category with a tax advantage. Someone has to have already built that. For nearly a decade, under a legal framework the U.S. still doesn’t have, someone has.
